Background {#Sec1}
==========

Atopic dermatitis (AD) is a common chronic, pruritic, inflammatory skin disease, mostly affecting children, with heterogeneous lifetime prevalence figures, ranging worldwide from 8 to 18% \[[@CR1]\]. Although its exact pathogenesis still remains unclear, it is well established that AD depends on a combination of genetic and environmental factors. In patients with AD, a genetically determined alteration of the skin barrier allows penetration of environmental factors, which are linked to a local - and systemic - immune dysregulation \[[@CR2]--[@CR4]\]. Taking into account the inflammatory nature of the disorder and the immune-based pathogenesis of the clinical picture (pruritus, skin hyperreactivity), topical corticosteroids (TCS) have always been the cornerstone of the treatment of AD \[[@CR4]\]. Appropriate use of TCS is characterized by a high efficacy, with reduced disease relapsing, and by a low incidence of local and systemic side effects \[[@CR5], [@CR6]\]. Nevertheless, it is very common, in clinical practice, to detect fear and anxiety regarding safety of TCS both among patients affected with AD and their families and among health care professionals \[[@CR7], [@CR8]\]. Such attitude towards TCS treatment, named TCS phobia, may lead to poor adherence to therapy and consequent treatment failure.

With the present multicenter study, we investigated prevalence and determinants of steroid phobia in a large group of Italian families of pediatric patients affected by AD.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a multicenter, cross-sectional study conducted in the dermatology units and general pediatric units of 9 pediatric centers located in 9 Italian cities (Ancona, Bologna, Cesena, Genoa, Lucca, Naples, Padova, Palermo, Rome, Bologna). The included centers represent some of the main Italian centers for pediatric dermatology.

From September 2013 to September 2014, families of pediatric patients with AD consulting for the first time at one of the above mentioned centers were consecutively enrolled. Inclusion criteria were age \<18 years and a diagnosis of AD. Exclusion criteria were presence of contraindications to the use of TCS (i.e. previous sensitization to TCS, active viral illness) and presence of other forms of dermatitis.

Prior to enrolment, one caregiver was asked to sign an informed consent to the study.

The study was approved by the Bambino Gesù Children's Hospital Ethical Committee (coordinator center) and by the Ethical Committees of all the other involved hospitals.

Questionnaire {#Sec4}
-------------

At enrolment, a self-filling questionnaire was given to one of the caregivers attending the patient.

The questionnaire included items on sociodemographic characteristics, previously identified atopic conditions, symptom duration, reason for the outpatient visit, clinical characteristics and SCORAD index at visit, quality of life assessment (DLQI), treatment prescriptions, previous therapeutic education.

Finally, the questionnaire included a standardized set of questions on fear of corticosteroids \[[@CR7]\], divided in 3 sections.

In the first section, fear of TCS was investigated, based on a 10-point visual analogue scale (VAS).

In the second section, specific fears and beliefs were investigated through 21 items. The level of agreement to each item was measured through a 4-point Lickert-scale.

In the third section, frequency of parents' behaviours regarding TCS treatment was investigated through 10 items based on a 4-point Lickert-scale.

Clinical parameters {#Sec5}
-------------------

AD was diagnosed according to Hanifin e Rajka criteria \[[@CR9]\]. Severity of AD was assessed through the SCORAD index \[[@CR10]\]. Pruritus was evaluated daily for a week after enrolment using the VAS score: from 0 (for no itch) to 10 (for maximum unbearable itch).

Statistical methods {#Sec6}
-------------------

We estimated a sample size of 302, based on an expected prevalence of TCS phobia of 80%, with a ±5% precision level and a 97% confidence interval.

The VAS scale used for expressing fear of corticosteroids was translated into categories as follows: 0--1: Not at all; 2--3: A little; 4--6: Moderately; 7--8: A lot; 9--10: Very much.

The ordinal qualitative variables (based on the 4-point Lickert scale) of the second and third section of the questionnaire were converted into quantitative, defined as a score ranging from 0 to 3 (0 representing a completely negative attitude towards TCS, 3 representing a completely positive attitude).

Additionally, we classified each item of the second and third part of the questionnaire into one category among efficacy, safety, compliance and quality of life. We then created 4 new "synthetic" variables, named after these categories. The value of the new variables was the sum of the scores of the items in each category, normalized to 100.

Proportions were calculated excluding missing values. Results of the descriptive analysis are reported as mean and SD or median and range as appropriate.

We performed a univariate analysis through simple linear regression to investigate factors associated with TCS fear, among the following: sociodemographic variables (child's age and sex, respondent's level of instruction); comorbidities (celiac diseases, thyroid diseases, asthma, allergic rhinitis, food allergy); clinical data including age at AD diagnosis, AD duration, AD evolution, AD treatment (emollients, systemic corticosteroids, topic TCS, systemic immunosuppressants, topic immunosuppressants, diet), SCORAD, median weekly pruritus, DQLI; having received therapeutic education; each item of the second and third section of the questionnaire and each of the synthetic variables (efficacy, safety, compliance and quality of life).

After checking for multicollinearity, multiple linear regression was used to create two multivariable models. Both models included fear of TCS as the dependent variable, and, as independent variables, those significantly associated with fear of TCS (*p* \< 0.05) at the univariate analysis. The first model included only the single items of the questionnaire (that were significantly associated with the outcome at the univariate analysis). The second model included the synthetic variables. Normality was verified with Shapiro-Wilk test. Results were considered statistically significant with *p* \< 0.05. Statistical analysis was performed using Stata 11.

Results {#Sec7}
=======

Patients' characteristics {#Sec8}
-------------------------

We consecutively enrolled a total of 300 patients with AD.

Sociodemographic characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients' demographic and clinical characteristicsFemales (n, %)14347,7Age (median, range)30.2 - 17Comorbidity (n, %)8327,7 celiac disease41,3 diabetes00,0 thyreopathy20,7 asthma3210,7 rhynitis3010,0 food allergy103,3 other165,3Years of age at AD diagnosis (median, range)0,40-13AD duration in years (median, range)1,80-15Disease evolution (n, %) stable4314,3 periodic relapses16454,7 worsening6822,7 improving299,7 irregular217,0Treatment (n, %) moisturizers24184,0 topical steroids23682,2 systemic steroids5619,5 topical immunosuppressants3110,8 systemic immunosuppressants103,5 diet8128,2 other3110,8SCORAD (n, %) mild11439,7 moderate12543,6 severe5218,1Therapeutic education (n, %)20167

Median age of patients was 3 years. 144/300 patients (48%) were females.

A large proportion of respondent caregivers had a high education level (80% had a high school or university degree).

Twenty-seven percent of the included patients had comorbidity, mainly asthma or allergic disorders (allergic rhinitis or food allergy).

Regarding AD, in most cases, the disease had been diagnosed during the first year of life (median age at AD diagnosis: 5 months), and the median AD duration at enrolment was 1.8 years. Most patients had a moderate-severe AD (61.7%). The mean pruritus score was 5 (SD: 2).

A total of 287 patients were taking a treatment for AD at enrolment. A large proportion of patients were on topical steroids (82.2%), while 84% were on moisturizers. Concerning other therapies, 56 patients were (19.5%) on systemic steroids, 31 (10.8%) on topical immunosuppressants and 10 (3.5%) on systemic immunosuppressants. Almost 30% of patients were treated with an elimination diet. Two thirds of respondents had received therapeutic education, either continuous or occasional.Table 2Response to questions on TCS specific fears and on behaviors regarding TCS useFears and beliefsCategoryI completely disagreeI don't really agreeI agree to a certain extentI completely agreeTCS are effective over a short time periodE12 (4%)25 (9%)84 (30%)155 (56%)TCS are effective over a long time periodE81 (30%)58 (21%)100 (37%)33 (12%)TCS pass into the bloodstreamS66 (25%)40 (15%)92 (35%)67 (25%)TCS can lead to infectionsS147 (56%)55 (21%)40 (15%)22 (8%)TCS make you fatS120 (44%)40 (15%)69 (25%)42 (15%)TCS damage your skinS59 (22%)44 (16%)104 (38%)65 (24%)TCS will affect my future healthS93 (35%)51 (19%)90 (33%)35 (13%)There is a dependency riskS90 (33%)35 (13%)84 (31%)62 (23%)I can become resistant to TCSS42 (16%)44 (17%)107 (40%)72 (27%)TCS become inefficient over timeE31 (12%)39 (14%)110 (41%)89 (33%)TCS calm symptoms but don't treat the causeE24 (9%)25 (9%)67 (24%)159 (58%)TCS make eczema worseE152 (57%)58 (22%)43 (16%)15 (6%)TCS stop the eczema from coming up to the surface of the skinE33 (12%)37 (14%)72 (27%)129 (48%)TCS can lead to asthmaS181 (72%)36 (14%)29 (11%)7 (3%)I don't know of any side-effects but I'm still afraid of TCSS43 (16%)43 (16%)102 (38%)82 (30%)TCS are more dangerous than CS in tablet formS177 (66%)37 (14%)35 (13%)18 (7%)TCS treatment takes time and effortE89 (32%)74 (27%)73 (27%)38 (14%)TCS treatment is complicatedQ157 (58%)57 (21%)38 (14%)19 (7%)TCS treatment helps me improve my quality of lifeQ26 (9%)27 (10%)122 (44%)100 (36%)TCS increase my well-beingQ36 (13%)31 (11%)115 (42%)91 (33%)The advantages of TCS use outweigh the disadvantagesQ23 (8%)44 (16%)120 (44%)87 (32%)Behaviors regarding TCS treatmentNeverSometimesOftenAlwaysI'm afraid of applying too much creamS76 (29%)114 (44%)58 (22%)11 (4%)I'm afraid of using the cream for too longS49 (19%)104 (40%)77 (30%)28 (11%)I'm afraid of putting cream on certain zones like the eyelids, where the skin is thinnerS47 (18%)70 (27%)71 (27%)73 (28%)It's more dangerous to use TCS on children than on adultsS42 (16%)72 (28%)75 (29%)72 (28%)If the doctor prescribed TCS then I would apply the prescriptionC31 (12%)67 (26%)53 (20%)109 (42%)I wait as long as I can before applying the treatmentC72 (27%)70 (27%)64 (24%)56 (21%)I stop the treatment as soon as I canC34 (13%)51 (19%)87 (33%)90 (34%)I am careful to rub the cream in well when I apply itS11 (4%)27 (10%)71 (27%)151 (58%)I avoid putting TCS on my child's handsS78 (30%)46 (18%)32 (12%)102 (40%)I need reassurance about TCSS44 (17%)72 (27%)61 (23%)87 (33%)*E* efficacy, *S* safety, *Q* quality of life, *C* compliance

Mean DLQI score was 3.

Descriptive and multivariate analysis {#Sec9}
-------------------------------------

Overall, a high proportion of patients reported having fears regarding TCS treatment: at the VAS scale, "No fear at all" was reported by 18.8% of the enrolled patients only (A little: 26.4%, Moderately: 36.8%; A lot: 13.7%; Very much: 4.3%). Responses to the other questionnaire items are reported in (Table [2](#Tab2){ref-type="table"}).

The multivariable analysis identified few items significantly associated with fear of TCS treatment: believing that TCS treatment advantages do not overweigh disadvantages (*P* = 0.011); believing that TCS may be dangerous independently from the specific side effect (*P* \< 0.001); moreover, TCS fear was associated with fear of applying too much cream (*P* = 0.001). Results of univariate and multivariate analyses are reported in Additional file [1](#MOESM1){ref-type="media"}.

When subgrouping the items into categories, items concerning safety were more associated with fear compared with items concerning efficacy, compliance or quality of life.

Discussion {#Sec10}
==========

In the present study, we show that, in Italy, fear of TCS is very common among families of pediatric patients affected with AD.

We investigated corticophobia in an exclusively pediatric population. Only few previous studies on TCS phobia have been conducted on a population of children \[[@CR11]--[@CR14]\].

According to our results, fear of TCS is not motivated by specific reasons: most respondents reported that, according to them, TCS are dangerous independently from the specific side effects, and the treatment disadvantages are not balanced by its advantages. In previous studies, the predominant concerns about TCS were cutaneous side-effects and failure to thrive \[[@CR7], [@CR15], [@CR16]\].

Old generation TCS had a high systemic absorption rate, especially in children \[[@CR17], [@CR18]\]. Therefore, their long-term or inadequate use commonly caused a variety of local and systemic side effects, including folliculitis, erythema, reduced skin thickness and/or skin atrophy, striae rubrae, Cushing-like syndrome \[[@CR19]\]. Such side effects are still stigmatized in the perception of the patients regarding this type of drug, despite the excellent safety profile of new generation TCS \[[@CR19], [@CR20]\]. Moreover, when appropriately used, new generation TCS are highly effective: they reduce inflammation, itching and relapse rate, thus dramatically improving the quality of life of the patients and their families.

Our study also shows that fear of TCS is related to the fear of applying too much cream. Thus, corticophobia may trigger a vicious circle leading to treatment failure: a reduction of compliance may cause prolonged and frequent relapses, which reduce trust in the treatment, thus further decreasing compliance.

Several studies highlighted the important role of the patient-doctor relationship in order to reduce fear of TCS \[[@CR7], [@CR11], [@CR14]--[@CR16]\]. We only investigated the effect of need of reassurance from the patient's doctor on TCS fear, and did not find any association. Nevertheless, as, according to our results, corticophobia is specifically directed towards treatment safety, it is mandatory that family pediatricians and general physicians dedicate a consistent time of the visit to identifying the patients' fear of TCS, in order to address misconceptions, thus improving the families' trust and compliance through evidence-based information.

Interestingly, 82% of our population was under TCS treatment, demonstrating that, despite fear, the parents were compliant to the prescription of their caregivers. Nevertheless, it is not possible to prove whether the use of TCS was adequate.

A large proportion of participants (two thirds) had received a therapeutic education for the management of atopic dermatitis. However, therapeutic education did not seem to affect fear of TCS among participants. In Italy, a therapeutic patient education program has been introduced in the last 5--10 years, in the third-level centers participating in the study. This education program aims at informing the families of pediatric patients about the disease course and at empowering them towards an autonomous therapeutic management of the disease \[[@CR21]\]. The therapeutic education includes information on the appropriate modalities for applying topical products and on the use of distraction techniques aimed at creating a relaxing environment and at transforming the dressing moment into a pleasant interaction between the child and his parent \[[@CR22]--[@CR24]\]; no specific information is actually given on the safety profile of TCS. This may explain the lack of association between therapeutic education and TCS fear. Therapeutic education sessions could actually be excellent contexts for addressing TCS fear with participating families, thus improving their knowledge on safety and effectiveness of new generation TCS, with a subsequent, possible reduction of TCS fear.

The present study has several limitations. The main limitation concerns selection bias. The patients were enrolled from amongst those presenting to the pediatric dermatology outpatient clinics of the above mentioned hospitals. Nevertheless, this is a multicenter study involving hospitals that are located in different Italian regions, therefore the sample should be sufficiently representative of the Italian population of pediatric patients with AD. Moreover, only a very limited number of families refused to answer to the questionnaire, nevertheless we cannot exclude that patients whose parents refused to answer to the questionnaire differed in terms of age and sex from those that agreed to enrolment. Another limitation concerns the score used to assess TCS phobia. We adopted the score proposed by Aubert-Wastiaux \[[@CR7]\]. The same score subsequently informed the production of a newer scale \[[@CR25]\], which had good psychometric properties, but was not available at the time of our study. The adoption of such scale might have yielded more precise results.

Conclusion {#Sec11}
==========

AD is a chronic disorder and its treatment, mainly based on topical agents, is a long-term "therapeutic management", rather than a common therapy. Awareness of AD treatments' side effects is crucial, nevertheless, truths and misconceptions regarding this issue should be precisely addressed in order to ensure compliance. A specific educational program should follow a holistic approach and establish a strong relationship between the patient's family and caregivers. In fact, the results of our study prove the need of implementing and focusing the therapeutic education on the use of TCS and to spread it to all professionals involved in the management of AD. It is mandatory that caregivers dedicate time to inform parents about the safety of the new generation products, whose main advantage is a clearly improved risk/benefit ratio.

Additional file {#Sec12}
===============

Additional file 1:Univariate and multivariate analysis results (dependent variable: TCS fear). (DOCX 22 kb)
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